1. Academic Validation
  2. Analysis of Serum Metabolites to Diagnose Bicuspid Aortic Valve

Analysis of Serum Metabolites to Diagnose Bicuspid Aortic Valve

  • Sci Rep. 2016 Nov 15:6:37023. doi: 10.1038/srep37023.
Wenshuo Wang 1 Aikebaier Maimaiti 1 Yun Zhao 1 Lingfei Zhang 2 Hongyue Tao 3 Hui Nian 1 Limin Xia 1 Biao Kong 4 Chunsheng Wang 1 Mofang Liu 2 Lai Wei 1
Affiliations

Affiliations

  • 1 Department of Cardiac Surgery, Zhongshan Hospital, Fudan University. 200032, Shanghai, China.
  • 2 State Key Laboratory of Molecular Biology, Shanghai Key Laboratory of Molecular Andrology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 200031, Shanghai, China.
  • 3 Department of Radiology, Huashan Hospital, Fudan University. 200040, Shanghai, China.
  • 4 Department of Chemistry, Laboratory of Advanced Materials, Fudan University, 200433, Shanghai, China.
Abstract

Bicuspid aortic valve (BAV) is the most common congenital heart disease. The current study aims to construct a diagnostic model based on metabolic profiling as a non-invasive tool for BAV screening. Blood serum samples were prepared from an estimation group and a validation group, each consisting of 30 BAV patients and 20 healthy individuals, and analyzed by liquid chromatography-mass spectrometry (LC-MS). In total, 2213 metabolites were detected and 41 were considered different. A model for predicting BAV in the estimation group was constructed using the concentration levels of monoglyceride (MG) (18:2) and glycerophospho-N-oleoyl ethanolamine (GNOE). A novel model named Zhongshan (ZS) was developed to amplify the association between BAV and the two metabolites. The area under curve (AUC) of ZS for BAV prediction was 0.900 (0.782-0.967) and was superior to all single-metabolite models when applied to the estimation group. Using optimized cutoff (-0.1634), ZS model had a sensitivity score of 76.7%, specificity score of 90.0%, positive predictive value of 80% and negative predictive value of 85.0% for the validation group. These results support the use of serum-based metabolomics profiling method as a complementary tool for BAV screening in large populations.

Figures
Products